Randialic acid B |
Catalog No.GC66363 |
L'acide randialique B, un composé triterpénoÏde, est un antagoniste du récepteur formyl peptide 1 (FPR1). L'acide randialique B bloque FPR1 dans les neutrophiles humains et atténue l'inflammation de type psoriasis in vivo.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 14021-14-8
Sample solution is provided at 25 µL, 10mM.
Randialic acid B, a triterpenoid compound, is a formyl peptide receptor 1 (FPR1) antagonist. Randialic acid B blocks FPR1 in human neutrophils and attenuates psoriasis-like inflammation in vivo[1].
Randialic acid B (0.1-3 μM; for 5 min) selectively inhibits reactive oxygen species production, elastase release, and CD11b expression in human neutrophils activated by FPR1. Randialic acid B inhibits the binding of N-formyl peptide to FPR1 in human neutrophils, neutrophil-like THP-1 cells, and hFPR1-transfected HEK293 cells, indicating FPR1 antagonism[1].
Randialic acid B acts competitively for its binding to the FPR1 receptor. The FPR1-downstream signaling such as Ca2+ mobilisation and activation of Akt and MAPKs is also competitively inhibited[1].
Randialic acid B shows significant cell-protective effects against H2O2-induced H9c2 cardiomyocyte injury[2].
Randialic acid B (10 mg/kg; i.v.; every other day; for 5 days) significantly reduces Imiquimod-induced psoriasis-like symptom, including epidermal hyperplasia, desquamation with scaling, neutrophil skin infiltration, and transepidermal water loss[1].
Animal Model: | BALB/c white female mice (20 g weight; 7-week-old) treated with Imiquimod[1] |
Dosage: | 10 mg/kg |
Administration: | i.v.; every other day; for 5 days |
Result: | Significantly reduced Imiquimod-induced psoriasis-like symptoms. |
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *